Antibody Information
General Information of This Antibody
| Antibody ID | ANI0ICVKZ |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | RFB4 |
|||||
| Synonyms |
CD22
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG |
|||||
| Antigen Name | B-cell receptor CD22 (CD22) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
EVQLVESGGG LVKPGGSLKL SCAASGFAFS IYDMSWVRQT PEKRLEWVAY ISSGG
GTTYY PDTVKGRFTI SRDNAKNTLY LQMSSLKSED TAMYYCARHS GYGSS YGVL F AYWGQGTLVT TSA Click to Show/Hide
|
|||||
| Light Chain Sequence |
DIQMTMTTSS LSASLGDRVT ISCRASQDIS NYLNWYQQKP DGTVKLLIYY TSILH
SGVPS RFSGSGSGTD YSLTISNLEQ EDFATYFCQQ GNTLPWTFGG GTKLEIK Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
RFB4-SMPT-dgA [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must have CD22+ (≥30%) B-cell NHL (excluding CLL, ALL, and hairy cell leukemia), measurable disease (excluding marrow-only involvement), and progression post-chemotherapy, with adequate organ function (CrCl >60 mL/min, bilirubin <1.5 mg/dL, EF ≥35% if prior doxorubicin).Key exclusions include HIV, CNS/pulmonary involvement, recent chemotherapy (<2 weeks), and transplant candidates. Required labs: SGPT <2x ULN, albumin >75% LLN, PS 0-2, and life expectancy ≥3 months.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00001271 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma
|
||||
References